{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for alpha root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Source:
INN:linvencorvir [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00622622: Phase 1 Interventional Completed Pancreatic Cancer
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Elpamotide is an anti-angiogenic cancer vaccine. It is an HLA-A*24:02-restricted epitope peptide of vascular endothelial growth factor receptor 2 (VEGFR-2) (RFVPDGNRI) and induces cytotoxic T lymphocytes (CTLs) against VEGFR-2/KDR. OncoTherapy Science was developing elpamotide for the treatment of solid tumors.
Status:
Investigational
Source:
NCT00004496: Phase 1 Interventional Completed Acute Renal Failure
(1999)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
alpha-MELANOTROPIN (also known as an alpha-melanocyte-stimulating hormone or alpha MSH) is an endogenous melanocortin 1-receptor agonist, which exclusively expressed in cells of the melanocytic lineage. alpha-MELANOTROPIN possesses anti-inflammatory properties and antagonizes proinflammatory mediators, including TNF-alpha, IL-6 and NO, and induces anti-inflammatory cytokine IL-10. alpha-MELANOTROPIN was studied in phase I clinical trial in patients with acute renal failure. In addition, this compound was assigned of orphan designation for the treatment of chronic beryllium disease.
Status:
Investigational
Source:
NCT01439568: Phase 2 Interventional Completed Extensive Stage Small Cell Lung Carcinoma
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01777165: Phase 2 Interventional Completed Acute Kidney Injury
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Modimelanotide is a melanocortinergic peptide drug derived from α-melanocyte-stimulating hormone (α-MSH) which was under development for the treatment of acute kidney injury. Modimelanotide had promising preclinical data, and a Phase II trial in patients undergoing cardiopulmonary bypass surgery showed a reduced incidence of acute kidney injury in subjects that received Modimelanotide. However, a Phase IIb, multicenter study of Modimelanotide in patients with chronic kidney disease who underwent cardiopulmonary bypass surgery failed to show a significant reduction in the incidence of acute kidney injury in subjects who received the drug, both by serum creatinine measurements and by novel biomarkers of tubular injury.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00572598: Early Phase 1 Interventional Completed Breast Cancer
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02965599: Phase 2 Interventional Terminated Arthritis, Rheumatoid
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
NCT02490774: Phase 2 Interventional Terminated Contraception
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03262389: Phase 2 Interventional Completed Multiple Myeloma
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
FLUDEOXYGLUCOSE is a fluorinated glucose analog. Its 18F radiolabelled form is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.
